Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...259260261262263264265266267268269...10661067»
  • ||||||||||  dexamethasone / Generic mfg.
    LOCAL ADOPTIVE CELLULAR IMMUNOTHERAPY WITH CYTOKINE-INDUCED KILLER (CIK) CELLS FOR HIGH GRADE GLIOMAS: A PILOT STUDY WITH LONG-TERM FOLLOW-UP AND POTENTIAL FACTORS FOR SURVIVAL BENEFITS () -  Sep 28, 2022 - Abstract #SNO2022SNO_438;    
    Gene expression profiles, expressions of cytokines and infiltrations of immune cells in tumors were investigated by RNA sequencing, an electrochemiluminescence assay and immunohistochemistry staining, respectively RESULTS Fever and symptoms of encephaledema occurred in 5 patients after local administration of CIK cells, and could be efficiently relieved by mannitol and dexamethasone...CONCLUSION Long-term survival of HGG patients could achieve after local administration of CIK cells into tumor cavity postoperatively. High expressions of cytokines and low infiltrations of M2 polarized macrophages in the tumors potentially benefited the CIK cell therapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort (Ballroom B) -  Sep 28, 2022 - Abstract #SNO2022SNO_198;    
    Our previous randomized study of neoadjuvant and adjuvant pembrolizumab versus adjuvant pembrolizumab in recurrent glioblastoma identified a molecular signature for ICI and suggested that neoadjuvant pembrolizumab improved survival (PMID30742122)...Patients receiving > 4mg dexamethasone, or with prior immunotherapy or anti-angiogenic therapy were excluded...This surgical window-of-opportunity paradigm allows for attribution of molecular effects to single agents. Future work will evaluate the differences in patient population, tumor characteristics, and address additional immune checkpoints and/or signaling pathways that can be targeted to augment the effectiveness of anti-PD1 in glioblastoma.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Trial completion date, Trial primary completion date, Combination therapy:  Isatuximab in Combination With Novel Agents in RRMM - Master Protocol (clinicaltrials.gov) -  Sep 27, 2022   
    P1/2,  N=72, Recruiting, 
    Initiation date: Jun 2022 --> Dec 2022 Trial completion date: Oct 2027 --> Jun 2028 | Trial primary completion date: Oct 2027 --> Jun 2028
  • ||||||||||  PT150 / The Pop Test & Palisades Therap
    Trial completion date, Trial primary completion date:  Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study) (clinicaltrials.gov) -  Sep 27, 2022   
    P1,  N=10, Recruiting, 
    Trial completion date: Oct 2027 --> Jun 2028 | Trial primary completion date: Oct 2027 --> Jun 2028 Trial completion date: Apr 2022 --> Jan 2023 | Trial primary completion date: Mar 2022 --> Jan 2023
  • ||||||||||  mycophenolate mofetil / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Trial completion date, Trial primary completion date, Biopsy:  I4BiS: 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation (clinicaltrials.gov) -  Sep 27, 2022   
    P3,  N=346, Recruiting, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Feb 2023 Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2024
  • ||||||||||  dexamethasone / Generic mfg., captopril / Generic mfg., valsartan / Generic mfg.
    Journal:  High Prevalence of Primary Aldosteronism in Patients with Type 2 Diabetes Mellitus and Hypertension. (Pubmed Central) -  Sep 24, 2022   
    Treatment with mineralocorticoid receptor antagonists (MRAs) induced a significant and permanent reduction of BP in all HDM-2 patients. Early diagnosis and targeted treatment of PA is crucial to prevent any aggravating effect on chronic diabetic complications.
  • ||||||||||  dexamethasone / Generic mfg., progesterone / Generic mfg.
    Review, Journal:  Differentiating Polycystic Ovary Syndrome from Adrenal Disorders. (Pubmed Central) -  Sep 24, 2022   
    It should be kept in mind that rapidly progressive hyperandrogenic manifestations such as hirsutism may be due to an androgen-secreting adrenocortical carcinoma. This review discusses the pathophysiology of androgen excess of both adrenal and ovarian origins; outlines the conditions which lead to androgen excess; and aims to facilitate the differential diagnosis of PCOS from certain adrenal disorders.
  • ||||||||||  prednisolone / Generic mfg.
    Journal:  Acute Idiopathic Blind Spot Enlargement Syndrome-New Perspectives in the OCT Era. (Pubmed Central) -  Sep 24, 2022   
    Two patients received weight-adapted oral prednisolone, which was gradually tapered over six to eight weeks...Early corticosteroid treatment may support outer retinal reorganisation, which can be followed with OCT in accordance with visual field restoration. This should be addressed in a prospective study.
  • ||||||||||  Zalain (sertaconazole) / Elder Pharma
    Clinical, Retrospective data, Journal:  A Meta-Analysis on the Effectiveness of Sertaconazole 2% Cream Compared with Other Topical Therapies for Seborrheic Dermatitis. (Pubmed Central) -  Sep 24, 2022   
    At 28 days since the beginning of the treatment, the sertaconazole regimen was associated with a significantly higher percentage of patients with mild SI and a lower percentage of patients with moderate or severe SI (odds ratio 0.51) than the other investigated treatments-hydrocortisone, ketoconazole, clotrimazole, metronidazole, pimecrolimus, and tacrolimus (odds ratio 1.95). In conclusion, treatment with sertaconazole 2% cream may represent an efficient alternative therapy for patients with SD.
  • ||||||||||  dexamethasone / Generic mfg., pentoxifylline / Generic mfg.
    Clinical, Preclinical, Journal:  Effects of Dexamethasone and Pentoxifylline on Mania-like and Depression-like Behaviors in Rats. (Pubmed Central) -  Sep 24, 2022   
    These results suggest that pentoxifylline may be a promising therapeutic intervention for patients with mood disorders. Taking into account the excellent tolerability profile of pentoxifylline in humans, it is warranted to conduct randomized clinical trials to investigate its therapeutic efficacy in patients with psychiatric disorders.
  • ||||||||||  fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
    Journal:  Development of an Add-On Device Using 3D Printing for the Enhancement of Drug Administration Efficiency of Dry Powder Inhalers (Accuhaler). (Pubmed Central) -  Sep 24, 2022   
    With salmeterol xinafoate and fluticasone propionate as model active pharmaceutical ingredients (API), the emitted API doses were used to assess the effectiveness of the add-on device...The use of the add-on device combined with a sufficient inhalation flow rate resulted in a larger pressure drop and airflow velocity at the blister pocket. As these characteristics are associated with powder fluidization, entrainment, and particle re-suspension, this innovative add-on device might be utilized to enhance the DPI emitted drug dose for patients with low inspiratory rates and to facilitate the provision of adequate drug doses to achieve the treatment outcomes.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  3D Printing of Triamcinolone Acetonide in Triblock Copolymers of Styrene-Isobutylene-Styrene as a Slow-Release System. (Pubmed Central) -  Sep 24, 2022   
    Thermorheological properties of the SIBS polymer (22.3 kDa, 38 wt % S) were adjusted to the printability of SIBS/TA mixtures (1-5% of TA), generating an effective release system effective for more than 60 days. Continuous drug release and morphological investigations were conducted to probe the influence of the 3D printing process on the drug release, enabling 3D printing as a formulation method for a slow-release system of Triamcinolone.
  • ||||||||||  dexamethasone / Generic mfg., dexamethasone injection / Generic mfg.
    Preclinical, Journal:  Influenza B Virus (IBV) Immune-Mediated Disease in C57BL/6 Mice. (Pubmed Central) -  Sep 24, 2022   
    The results showed that the immune response to IBV is the major cause of morbidity, mortality, lung pathology, and viral clearance. Importantly, the results suggest that a robust lung CTL response and associated leukocyte influx contribute to disease.
  • ||||||||||  netupitant (Ro 67-3189) / Helsinn, Otsuka
    Journal, CINV:  Netupitant-Palonosetron (NEPA) in Preventing Chemotherapy-Induced Nausea and Vomiting: From Clinical Trials to Daily Practice. (Pubmed Central) -  Sep 24, 2022   
    This review provides an overview of CINV, evaluates the accumulated evidence of NEPA's antiemetic activity and safety from clinical trials and real-world practice, and examines the preliminary evidence of antiemetic control with NEPA in daily clinical settings beyond those described in pivotal trials. Moreover, we review the utility of NEPA in controlling nausea and preserving patients' quality of life during chemotherapy, two major concerns in managing patients with cancer.
  • ||||||||||  Ozurdex (dexamethasone intravitreal implant) / AbbVie
    Clinical data, Journal:  Clinical Outcomes of Patients with Endophthalmitis after Dexamethasone Intravitreal Implant. (Pubmed Central) -  Sep 24, 2022   
    Endophthalmitis following intravitreal steroid injections may occur more frequently than other intravitreal injections. Dexamethasone-attributed endopthalmitis remains uncommon, and prompt intravitreal antibiotic treatment appears to be effective in this series.